In patients with advanced non–small cell lung cancer (NSCLC) and programmed death ligand 1 (PD‐L1) expression of at least 50% of tumor cells, pembrolizumab has been reported to achieve significantly longer progression‐free and overall survival and fewer adverse events than platinum‐based chemotherapy (KEYNOTE‐024).1 This evidence concerns the gene CD274 and neoplasm.